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ABSTRACT The literature on innovation and interactive learning has tended to
emphasize the importance of local networks, inter-firm collaboration and knowledge
flows as the principal source of technological dynamism. More recently, however, this
view has come to be challenged by other perspectives that argue for the importance
of non-local knowledge flows. According to this alternative approach, truly dynamic
economic regions are characterized both by dense local social interaction and
knowledge circulation, as well as strong inter-regional and international connections
to outside knowledge sources and partners. This paper offers an empirical
examination of these issues by examining the geography of knowledge flows
associated with innovation in biotechnology. We begin by reviewing the growing
literature on the nature and geography of innovation in biotechnology research and
the commercialization process. Then, focusing on the Canadian biotech industry, we
examine the determinants of innovation (measured through patenting activity), paying
particular attention to internal resources and capabilities of the firm, as well as local
and global flows of knowledge and capital. Our study is based on the analysis of
Statistics Canada’s 1999 Survey of Biotechnology Use and Development, which
covers 358 core biotechnology firms. Our findings highlight the importance of in-
house technological capability and absorptive capacity as determinants of successful
innovation in biotechnology firms. Furthermore, our results document the precise
ways in which knowledge circulates, in both embodied and disembodied forms, both
locally and globally. We also highlight the role of formal intellectual property
transactions (domestic and international) in promoting knowledge flows. Although we
document the importance of global networks in our findings, our results also reveal
the value of local networks and specific forms of embedding. Local relational linkages
are especially important when raising capital—and the expertise that comes with
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it—to support innovation. Nevertheless, our empirical results raise some troubling
questions about the alleged pre-eminence of the local in fostering innovation.
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Introduction: The Geography of Innovation in the Learning Economy
With the advent of the learning economy, it is widely agreed that
competition between firms is increasingly based on the production,
appropriation and distribution of knowledge. While this is true of all
industries to some extent—even older, more traditional economic activities
can benefit from the adoption of more innovative products and production
processes—it is especially so for the most knowledge-intensive economic
activities.
Biotechnology, as a highly science-based sector, is one of the most
knowledge-intensive forms of activity in the contemporary economy. Its
emergence is expected to have a major impact on regional and national
economies, both directly and indirectly. The production of biotechnology
products represents a relatively new and significant growth phenomenon
on its own. Over the long run, the growth potential associated with the
wider diffusion and use of biotechnology products and processes, and their
convergence with information technologies, nanotechnologies and other
applied sciences, is probably even greater. In this sense, biotechnology
appears to have the characteristics of a core technology, with the potential
to underpin a new technoeconomic paradigm.
It is therefore not surprising that the innovation process within
biotechnology firms has become a subject of major interest to social
scientists. Despite this recent interest, however, we are still far from a
consensus on the nature of the innovation process in this industry, and it is
the geography of this process that seems to be at issue. On the one hand,
some see this process as a global battle between several major players. In
this view, the very high degree of knowledge intensity in this industry
means that there is a strong ‘‘science push’’ along the trajectories of a
linear model of innovation from the university laboratory to the market-
place. Large up-front costs associated with multi-year research and
development (R&D) processes, followed by expensive regulatory reviews
and trials, raise barriers to entry. Hence, large firms operating on a
global scale are the dominant players. While there may be certain
acknowledged geographical centres of research excellence, their loca-
tional pull is diminished by the efficient international circulation of scientific
knowledge in codified form, in the form of journals, conferences, patents,
technology licences and other well-established practices of research
dissemination.1
At the same time, there is evidence of a paradoxical development in the
knowledge economy: knowledge-intensive economic activities—the most
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potentially footloose of all activities—exhibit high levels of geographical
concentration. Indeed, the most knowledge-intensive of these activities
seems to show the highest degree of geographical concentration. In the
case of biotechnology, this pattern of spatial concentration appears to be
strong and, if anything, becoming stronger rather than weaker over time
(Feldman, 2001).
This locational tendency towards geographical clustering appears to be
consistent with a large literature in economic geography and industrial
economics attesting to the role of agglomeration, clustering and localized
learning in fostering innovation and dynamic economic growth (Maskell and
Malmberg, 1999; Storper and Venables, 2002). The key idea here is that, if
innovation as an activity has become increasingly interactive and socially
organized (in contrast to more traditional conceptions based on a linear
model), then geographical concentration of the relevant actors will facilitate
this process of learning-by-interacting. Such dynamics may help to explain
why, for example, there appear to be strong spatio-temporal spillover
effects in the knowledge production process in biotechnology and related
sciences (Feldman, 2000), despite the ready codifiability and accessibility
of research findings on a global basis.
While arguments concerning the importance of localized learning
dynamics have acquired the status of ‘‘received wisdom’’ in recent years,
some economic geographers have also expressed considerable unease
with the idea that learning processes are exclusively local (Amin, 2000;
Allen, 2001). While many still acknowledge the critical role of localized
learning in the innovation process, there is a growing recognition that
locally based learning is likely to be most effective when the actors involved
remain fully open to new knowledge flows from around the world. From an
evolutionary perspective, such inflows serve to increase the diversity of
ideas within the local knowledge base, leading to potentially richer
innovation dynamics (Malmberg and Maskell, 2002). In a recent paper,
Bathelt et al. (2004) argue that these non-local connections are far from
randomly distributed across the globe, but can be thought of as global
‘‘pipelines’’ extending between centres of localized learning, and but-
tressed by corporate links effected by the large global players in sectors
such as biotechnology. Such pipelines, in their view, are essential
complements to the ‘‘local buzz’’ that is produced and reproduced in
agglomerated centres where innovative activity is concentrated. Both
1 In a recent overview of the ‘‘geography of innovation’’ literature, Asheim and Gertler (2005:
296–298) note that biotechnology draws primarily upon ‘‘analytical’’ forms of knowledge
that, at least in theory, are relatively easily codified and transmitted across long
geographical distances and cultural/institutional divides. However, they also note the
marked tendency for biotech innovation to cluster geographically, and offer further insights
as to why this might be the case, emphasizing the continuing importance of local networks
and relations, as well as the growing importance of quality of place in attracting and
retaining the highly educated people that typically work in this sector.
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geographies are essential to ensure the innovative dynamism of
participating firms over time.
The purpose of this paper is to advance our understanding of the
innovation process within the biotechnology industry, one of the most
knowledge-intensive of all industries in today’s economy. The goal is to
develop a better sense of the interplay or balance between global and local
forces and flows, thereby enabling us to examine the very interesting
conceptual arguments concerning local buzz and global pipelines through
the lens provided by a unique empirical example: a recent national survey
of biotechnology firms in Canada. In the following section we review
the recent literature on the nature and geography of innovation and
commercialization in biotechnology, enumerating some unresolved ques-
tions and hypotheses that emerge from this literature. Following this, we
discuss the unique source of data used for the empirical analysis, the 1999
Canadian Biotechnology Use and Development Survey, and present our
findings. We conclude this paper with a discussion of the conceptual and
policy implications arising from this analysis.
The Spatial Structure of Knowledge Production and Circulation in
Biotechnology
Competence-based views of the firm (Penrose, 1959; Kay, 1993;
Cohendet et al., 1999) argue that the innovative performance of the firm
depends on the resources and capabilities it acquires or develops, in the
form of investments in R&D, skilled human capital, and organizational
routines, relationships and other practices. Some of the firm’s capabilities
may also be developed through interaction with other firms or institutions
external to the firm itself, through a process that has come to be known as
learning by interacting (Lundvall and Johnson, 1994). Restating this in a
slightly different way, the ‘‘resources’’ that are critical to the firm’s success
may be inside or outside the firm. If the latter, then the next question is:
where are these crucial ‘‘relational resources’’ most likely to be found?
Previous research on innovation in biotechnology firms suggests that
access to knowledge and capital are essential determinants of firms’
research capabilities and their success in commercializing the outputs of
such research. Classic studies of the emergence of the US biotech industry
support the view that knowledge spillovers from universities are key to firm
start-ups (Zucker and Darby, 1996; Zucker et al., 1998a, b; Feldman, 2001;
Prevezer, 2001). Empirical evidence suggests that these knowledge flows
are highly localized. For example, Zucker et al. (1998a) find that the
number of products in development by firms is positively and significantly
related to the number of university stars2 in their geographical area. They
argue that star scientists do not freely give away their intellectual property
but instead enter into contractual arrangements with existing firms or start
their own firms to reap the economic returns from their scientific
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discoveries. Their analysis indicates that these scientists work with or
create firms within commuting distance of their home or university (Zucker
et al., 1998a).
Similarly, Feldman (2001) reports that when scientists in her study were
asked where they would locate given unlimited choice, most responded
that even though they could locate anywhere in the world (as they were
part of global scientific networks) they generally want to ‘‘stay put’’. Using
the literature on clusters and regional innovation processes, Feldman
(2000: 389) argues that biotech firms are highly concentrated geographi-
cally to reduce the distance over which interaction and communication are
conducted, and to enhance the coordination of tasks. These aspects of
clustering are particularly important for individuals starting a new enterprise
who seek to minimize disruption and uncertainty (Feldman, 2001).
Moreover, previous research indicates clustering is not only about reducing
transaction costs and minimizing risks but also about access to knowledge.
Delaney (1993, quoted in Feldman, 2001: 350) finds that ‘‘most biotechs
use information sources (within a 50-mile radius of the firm)’’.
The importance of spatial proximity between university-based scientists
and companies with the capabilities to commercialize their research is
underscored by recent developments within the pharmaceuticals indus-
try—most notably the announcement in May 2002 that Novartis, the Swiss
pharmaceuticals group, was moving its research operations to Cambridge,
Massachusetts. According to industry analysts, their decision to invest in
Cambridge was motivated by the concentration of genomics expertise in
the Boston area. This expertise comes in at least three different forms:
university and hospital researchers (key producers of potentially commer-
cializable intellectual property), rapidly growing biotech companies such as
Biogen, Vertex and Millennium (potential partners in collaborative
research), and graduates from world-renowned institutions such as MIT
and Harvard (Dyer, 2002b).3 Not surprisingly, the US$250 million Novartis
facility, large enough to house 400 scientists, has been constructed within
walking distance of MIT’s main complex of buildings.
Access to venture capital (VC) is another key factor emerging from
prior research on innovativeness and performance in biotechnology, since
this key input provides both the investment capital and the entrepreneurial
and managerial know-how necessary for commercial success (Zucker
et al., 1998b; Niosi, 2000a, b; Cooke, 2001b; Powell et al., 2002). Firms
with sufficient access to ‘‘patient’’, ‘‘knowledgeable’’ capital of this sort are
more likely to have the managerial and financial resources available to
realize their innovation goals, and this is especially relevant for small,
2 Star scientists are defined as outstanding scientists who combine scientific productivity (as
measured by number of journal articles while affiliated with the firm) with specific knowledge
of the new technique for the commercialization.
3 Dyer (2002b: 13) quotes Daniel Vasella, chairman of Novartis, as observing that ‘‘the
biggest pool of untapped scientists and hospital research was in the Boston area’’.
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recently established biotech start-ups with limited internal financial
resources. A large body of research suggests that the geographical
distribution of VC available for biotech firms is also highly concentrated.
Cortright and Mayer (2002) report that since 1996, 75 percent of new VC
investment in the USA was located in the five largest biotech clusters
(Boston, San Francisco, San Diego, Seattle and Raleigh-Durham).
Analyzing the biotech industry directory (BioScan) and Pratt’s Guide to
Venture Capital, Powell et al. (2002) also find that over 50 percent of
biotech firms receive local VC support. Similarly, Niosi notes that in
Canada ‘‘biotechnology firms tend to cluster in regions where venture
capital is abundant’’ (Niosi, 2000a: 13). In a recent, more detailed analysis,
Niosi and Dalpe´ (2003) demonstrate that Canada’s two largest biotech
clusters—Toronto and Montreal—show high degrees of local sourcing
when it comes to venture financing. On the other hand, smaller Canadian
centres exhibit considerably stronger dependencies on external VC
sources due to the relatively undeveloped nature of supporting sectors in
the local cluster.
The strong clustering of firms around VC sources can be partly
explained by the risky nature and lengthy time horizon of investments in
bioscience companies: reaping the fruits of such investments may take
years. For example, Cooke (2002a) reports that the transformation of
scientific research into commercial products can take over 10 years of
trials. Moreover, most of these innovations are highly specialized and
require investors to be knowledgeable about both the science involved and
the competence of the lead researchers. Finally, venture capitalists provide
more than just capital: they are also vital sources of managerial expertise to
help ensure successful product and business development. Furthermore,
Powell et al. (2002: 294) argue that experienced VCs use their abundant
contacts to provide referrals to specialized sources of expertise, such as
patent lawyers and consultants. Consequently, proximity between
researchers and VC fosters trust and the continuing exchange of
knowledge.
Even though the biotech industry is clearly one of the most
geographically concentrated forms of economic activity, there is a growing
appreciation that non-local (national and global) linkages are essential to
successful innovation. The evidence to support this argument, however, is
somewhat ambiguous. A number of researchers argue that, while
biotechnology research is highly concentrated, relationships in the
commercialization phase span longer distances (Niosi, 2000b; Prevezer,
2001; Cooke, 2002a; Powell et al., 2002). Maturing biotech firms seek
deals with large pharma corporations who will invest in transforming their
innovations into products. Cooke (2002a) and Prevezer (2001) argue that
some firms also seek customers and VC globally and nationally, as well as
regionally.
Local partnerships, on the other hand, are increasingly seen as being
especially critical for developing basic research (Niosi, 2000b), and for
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creating a critical mass of research capability (Cooke, 2002a). Powell et al.
(2002) find that locally funded firms are smaller, younger and more
science-focused (as indicated by the number of PhDs and MDs they
employ). These findings, together with data showing that early stage
companies are more reliant on local (vs. non-local) VC firms, lead Powell
et al. to conclude that local VC support is more important at the early
stages of a company’s development. Firms that have reached more
advanced commercial stages of development are more likely to attract
external financing from afar.
The age of a firm is a factor not only among biotech companies but also
among the VC firms themselves. Powell et al. find that as these firms grow
older and larger they tend to invest more in younger and more distant
biotech companies. Although VC is concentrated in Boston, New York and
the San Francisco Bay Area, in the last decade New York and Bay Area
companies have been increasingly branching out of their own areas to
finance firms in each other’s backyard and in the Boston area. Boston VC
companies, in contrast, have shown a stronger tendency to invest locally.
Cortright and Mayer (2002), in conducting a comprehensive survey of
American biotech companies and regions, come to a somewhat different
conclusion about the localization of research and VC. They find that
research activity (measured through patenting and NIH funding for medical
schools) is not very highly concentrated spatially, although ‘‘commercia-
lization efforts remained highly concentrated’’ (p. 33). In contrast to Niosi
(2000b), Prevezer (2001), Cooke (2002a) and Powell et al. (2002),
Cortright and Mayer’s evidence highlights the concentration of VC. They
argue that the critical factor in commercializing basic research products is
the
very high concentration of capital flows in biotech centers: the nine leading
biotech regions account for 88 percent of all venture capital for biopharma-
ceuticals, 92 percent of the most active biotechnology venture capital firms,
and 96 percent of the dollar value of research alliances with pharmaceutical
firms. (Cortright and Mayer, 2002: 33–34)
Moreover, four metropolitan areas received over 80 percent of the value of
all research contracts.
The above inconsistencies related to the geography of knowledge and
capital flows might be resolved by acknowledging that even though biotech
firms forge strategic alliances with far-away partners, these non-local
alliances are targeted at a few locales, where the specific competence,
capital or other required resources are concentrated. For example, Powell
et al. (2002) suggest that there are four key centres in which capital
circulates (Boston, New York, the San Francisco Bay Area and San Diego).
Even though capital flows between these centres and to a minor extent
outside them, they still dominate the biotechnology knowledge and capital
flows. The geographical focus of the researchers may also explain some of
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the discrepancies in the evidence. Whereas Cortright and Mayer focus on
American firms, Niosi (2000b) and Cooke (2002a) extend their evidence to
Canada and Europe, respectively. It is possible that the more limited
funding capabilities in Europe and Canada require companies there to
reach out to large foreign-owned pharma corporations to improve their
basic research and commercialization efforts.
In addition, Cortright and Mayer’s finding that research is dispersed, in
contrast to previous work that finds high degrees of regional concentration,
may be a reflection of the maturation of the industry over time. Whereas
Zucker and Darby and their collaborators focused on the birth of firms in the
late 1980s and early 1990s, Cortright and Mayer examine the current state
of a maturing industry.
The above review raises a number of interesting issues for the current
study. First, it is clear that there is very little consensus in the literature
concerning the relative importance and role of local vs. non-local sources
of knowledge and capital in this industry. Second, analyses that focus on
the geography of these flows have tended to downplay the internal
characteristics and capabilities of the firms themselves. Clearly, a
resource- or competence-based view of the firm suggests that our analysis
should attempt to capture the influence of internal capabilities as well as
those that are generated through interaction with external actors (both local
and non-local). Indeed, following Cohen and Levinthal’s (1990) influential
argument, the presence of well-developed internal capabilities and
resources will enhance the absorptive capacity of the firm—that is, its
ability to make productive use of new knowledge and ideas from external
sources. Third, in a knowledge-intensive industry such as biotechnology,
the most important input to the generation of successful new products is
undoubtedly highly educated people (embodied knowledge). Therefore, it
stands to reason that any analysis of innovation in biotechnology requires a
strong focus on human resources and labour market practices.
A recent report documenting the strengths, weaknesses and chal-
lenges facing the Canadian biotech industry highlights many of these
issues (Ernst and Young, 2002).4 By most accounts, Canada is home to
the second largest collection of dedicated biotech firms in the world after
the USA (Dyer, 2002a). Among Canada’s strengths, the report emphasizes
good knowledge infrastructure (universities and research centres), world-
class science and technology, well-established tax incentives for R&D, a
favourable exchange rate relative to US and European currencies, a high
quality of life that helps attract and retain talented workers, and a
geographical concentration of facilities, research and skills in a relatively
small number of centres (with Toronto, Montreal and Vancouver leading
the way). Among the industry’s weaknesses and challenges are thin
4 These highlights are a product of the Canadian Biotechnology Commercialization
Roundtable organized by Ernst and Young in March 2002, which brought together industry
members and analysts.
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domestic capital markets which make it difficult to raise capital and find
investment partners, lack of specialization by investment funds, the
relatively small size of the Canadian market, a shortage of scientists and
managers with experience in biotech start-ups, a relatively weak
entrepreneurial culture, and lengthy approval and testing processes.
Potential threats facing the industry are its consolidation through
acquisitions by foreign firms, a potential ‘‘brain drain’’ to the USA and
‘‘uncompetitive’’ regulatory processes.
Determinants of Innovation in Biotechnology Firms: Data and
Variables
To examine these issues and hypotheses we use a unique database that
documents innovation performance and other characteristics of biotech-
nology firms in Canada: Statistics Canada’s 1999 Survey of Biotechnology
Use and Development. The survey was conducted in the spring of 2000
and was designed to gather data from two distinct groups of firms: those
that use biotechnologies as part of their day-to-day operations, as they
would use any other factor of production, and ‘‘core’’ biotech firms—firms
that are conducting an active R&D program in biotechnology and consider
biotechnology central to their activities (McNiven, 2001a). The latter group
(consisting of 358 core firms) is the focus our analysis, and is believed to
be representative of the entire core firm population, based on size, sector
and province (see Tables 1–3).
Based on the literature reviewed in the previous section, we
hypothesize that the likelihood of innovation is greater for firms that have
assembled greater in-house resources and capabilities (which will also
enhance their capacity to absorb cutting-edge knowledge from external
sources). Therefore, such firms are expected to engage more intensively in
R&D, dedicate a higher proportion of their in-house human resources to
scientific and technical expertise, and devote greater resources to the
recruitment of skilled personnel. We would also expect the probability of
innovating will be greater for firms that are well supported by their local
milieu, but also link themselves effectively into global networks of
knowledge, capital and people. Hence, such firms can be hypothesized
Table 1. Number of core biotech firms by size, Canada, 1999
Number of firms
Small (50 or less employees) 270
Medium (51–150 employees) 51
Large (151 or more employees) 37
Total 358
Source: McNiven (2001a).
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to have better access to sufficient capital resources (particularly ‘‘patient’’
capital), utilize sources of tacit as well as codified information, and
collaborate with local partners but also reach out to external innovation
partners and sources of knowledge.
All 358 core biotech firms in the survey can be considered innovative, in
the sense that they were (by definition) using at least one of a list of
biotechnologies in their operations at the time of the survey. Not all of the
firms, however, had successfully produced a new product or process. For
the purposes of this analysis, patenting is used as an indicator of tangible
output from innovation in biotechnology. Previous analysis of the 1999
Biotechnology Use and Development Survey (McNiven, 2001b) indicates
that, of the nearly 8,000 pending and existing patents held world-wide by
Canadian biotech firms (3,706 existing, 4,259 pending), 2,300 were held or
pending in Europe, followed by the USA (2,166) and Canada (1,626).
Table 2. Number of core biotech firms by sector, Canada, 1999
Number of firms
Human health 150
Agriculture 90
Natural resources 18
Environment 35
Aquaculture 14
Bio-informatics 18
Food processing 29
Other 4a
Total 358
aUse with caution. Unreliable due to high coefficient of variation.
Source: McNiven (2001a).
Table 3. Number of core biotech firms by province, 1999
Number of firms
British Columbia 71
Alberta 28
Saskatchewan 16
Manitoba 6
Ontario 111
Quebec 107
Atlantic Canadaa 19
Canada 358
aIncludes Nova Scotia, Prince Edward Island, New Brunswick and Newfoundland.
Source: McNiven (2001a).
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Moreover, McNiven reports that although nearly 75 percent of biotech firms
are small, they held only 34 percent of patents. Large firms, on the other
hand, held over half of the pending and existing patents in 1999 (45 percent
of patents in the USA and 60 percent of patents in Europe).
The use of patenting as an indicator of innovation is consistent with a
large body of work investigating the nature and geography of innovation in
biotechnology and the biosciences more broadly (Zucker et al., 1998a;
Feldman, 2000, 2001; Niosi and Bas, 2001; Levin et al., 2001).5
Consequently, two dependent variables were formulated to measure
innovation. The first is a dichotomous variable [INNOVATION—Y/N]: ‘‘yes’’
if the firm held one or more patents in any geographic region of the world
and ‘‘no’’ if the firm had no existing or pending patents. A second variable
[INNOVATION INTENSITY] captures the intensity of innovation, measured
as the number of existing or pending patents (again, in all geographic
regions), divided by the number of biotech employees to remove the
possible effects of firm scale on the sheer volume of patenting activity.
Based on the hypotheses outlined above, eight groups of explanatory
variables were created: R&D expenditures per biotech employee
[RDSPEND] which measures the R&D intensity of the firm. In-house
scientific capability is measured as the number of biotech employees
working in R&D as a proportion of total biotech employees [INHSTECH].
The hypothesis regarding dedication of greater resources to recruitment of
skilled personnel is examined using three variables: the number of different
recruiting methods used to fill biotech positions [BIORCRT], problems
encountered when searching for new human resources [OBSTHR] and the
number of biotech staff hired from outside Canada, as a proportion of total
biotech related employment [KNOWFLWGG]. We can also regard this last
variable as an indicator of ‘‘embodied’’ international knowledge flow, since
the international mobility of highly skilled labour is likely to be a very
important channel for the circulation of biotech knowledge.
Since it was hypothesized that innovative firms utilize a broader range
of information and knowledge sources than non-innovative ones, we
5 The success of biotechnology firms is often measured by their innovative output rather
than by their revenues or profits. Zucker et al. (1998a) point out that revenues are generally
non-existent in the young biotech industry and are therefore of limited use as an indicator of
firms’ success. Innovative outputs, on the other hand, can indicate the ability of a firm to
attract VC that in turn allows a firm to develop and commercialize the fruits of its research.
Zucker et al. suggest that innovation can be measured by looking at the number of products
in development, the number of products on the market and net growth in employment.
Nevertheless, they and others agree that patents are perhaps the most useful predictor of
commercial values and future returns, and that patents are key to attracting VC to further
develop or commercialize innovative products (Niosi, 2000b). Notwithstanding this
consensus, it should also be acknowledged that patents as a measure of innovation are
subject to some well-known limitations. Many patents are never commercialized. For many
forms of innovation, patents may offer only partial protection of intellectual property; for
others, patents may be wholly infeasible or impractical (see Teece, 1986; Levin et al., 1987;
Klevorick et al., 1995).
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created four information and knowledge variables: internal [INTERNAL],
codified [CODIFIED], tacit/personal (‘‘embodied’’) [TACIT] and government
[GOVERNMENT]. The Biotech Survey asks firms to rate the importance of
various sources of information to their firms on a scale of 1 (low) to 5 (high).
If the firm ranked the information source above 3 we computed that source
as important.6
The hypothesis regarding the relationship between collaboration and
innovation was also tested using three variables: the number of
collaborative arrangements in which a firm participates [NUMBER OF
COLLABORATIVE AGREEMENTS], whether these arrangements were
‘‘local’’ or not,7 and whether or not the firm was spun off from another
company [SPINOFF]. The survey also collects useful information on flows
of intellectual property rights that enables us to track the geography of
knowledge inflows and outflows explicitly. To test the importance of
domestic vs. international knowledge flows, four variables measuring the
presence (yes/no) of inflows and outflows of intellectual property (IP) rights
between foreign and Canadian firms were used [IPINF—inflow from foreign
firms, IPOUTF—outflow to foreign firms, IPINC—inflow from Canadian
firms, IPOUTC—outflow to Canadian firms].
The last two groups of variables focused on the availability of capital
resources, again measured by three different measures—capital raised per
biotech employee [CAPITAL RAISED PER EMPLOYEE], the amount of
capital raised from ‘‘private’’ or ‘‘relational’’ (and therefore most likely local)
sources—that is, the percentage of total capital that was raised from angel
investors/family/friends, VC and collaborative alignments [CAPITAL
MARKET LINKAGES], and whether or not the firm identified access to
capital as a major obstacle to growth [OBSTACLE CAPITAL]. To capture
the influence of ‘‘life cycle’’ effects on the likelihood of innovation
(patenting), we introduced a set of variables reflecting the stage of
development of products and processes. These represent the number of
products a firm has in a specific stage of the product development cycle, as
a proportion of its total number of products [STAGE—RD, STAGE—
PRECLINICAL, STAGE—REGULATORY, STAGE—APPROVED]. Our
expectation would be that firms that have advanced to later stages of
6 The following are the categories listed in the survey which correspond to each of the
variables: Internal—internal sources/staff or parent/subsidiary firm; Codified—academic
journals/trade publications, library/literature search, database retrieval services; Tacit/
personal—universities/colleges/private training institutes, personal contact with others,
other companies, professional/industry associations, conferences/workshops/trade shows;
and Government—federal agencies, provincial agencies.
7 The survey asks firms for the location of their collaborative partners by country. Therefore,
for the purpose of this analysis, ‘‘local’’ partners were defined as those within Canada.
Previous work (Ernst & Young, 2002) confirms that biotech firms are highly concentrated in
a few Canadian city-regions, with Toronto, Montreal and Vancouver dominating. This
suggests that there is a high likelihood that a partner in the same country is also located
within the same city-region.
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product/process development would be more likely to have generated
patents since, on the whole, they are likely to be older and better able to
generate resources internally to support further innovation. Finally, in order
to capture the influence of any other resources and capabilities not already
explicitly measured, we included a variable to reflect the size of the firm,
measured by number of employees [SIZE].
Analysis and Results
For the dichotomous form of the dependent variable (which measured
whether or not a firm has patented) we conducted a logistic regression (see
Table 4). The results show that innovating firms dedicate more efforts and
resources to HR recruiting, that is, that they use a higher number of
different recruiting methods to fill vacant biotech positions. Having
employed more recruiting methods, however, innovative biotech compa-
nies also report encountering more obstacles in these efforts—perhaps
because their human resources needs are more demanding. Contrary to
previous research that highlights the importance of tacit sources of
information, the use of such sources did not turn out to be a significant
predictor of innovativeness. Moreover, even though our analysis shows
that innovative biotech firms in Canada are more likely to have spun off
from larger firms, biotech innovators are actually less likely to rely on
internal sources of information, including the staff from the parent or
subsidiary firm. Patenting firms, however, make heavier use of codified
sources of knowledge, such as academic journals, trade publications or
database and library resources compared to firms that do not patent.
Strikingly, and suggestive of the importance of global pipelines, the
data show that knowledge networks of innovative biotech firms are non-
local—indeed global. Firms that patent are more likely to tap into global
knowledge flows of the embodied variety—they hire a significantly larger
proportion of their biotech workers from outside of Canada. They are also
more likely to grant IP rights to foreign firms, suggesting that commercia-
lization is reliant on relationships with companies outside Canada.
Alternatively, one could say that patenting firms are more likely to produce
new knowledge that is recognized to have commercial value in the
international marketplace. Innovators are also more likely to participate in
collaborative agreements. Other variables related to VC did not show a
clear direction and were not significant.
Finally, patenting firms are more likely to have a higher proportion of
their projects in later (regulatory review) stages of development. This
suggests that more mature firms are more likely to have produced tangible
outputs from innovation.
Results were similar when innovation was measured by its intensity
(number of patents), rather than by the simple presence or absence of
patents (see Table 5). Firms that patent more intensively were found to
dedicate more effort and resources to human resources recruiting, that is,
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Table 4. Logistic regression analysis: existing/pending patents—yes/noa
Variable B Wald Sig. Exp(B)
RDSPEND 0.000 1.933 0.164 1.000
INHSTECH 0.042 0.014 0.905 1.043
BIORCRT 0.434*** 21.465 0.000 1.543
KNOWFLWGG 7.005** 5.639 0.018 1,102.506
OBSTHR 0.630** 4.229 0.040 1.878
INTERNAL 21.028** 5.773 0.016 0.358
CODIFIED 0.577*** 6.220 0.013 1.781
TACIT 20.254 2.695 0.101 0.776
GOVERNMENT 0.143 0.637 0.425 1.154
NUMBER OF COLLABORATIVE
AGREEMENTS
0.112* 3.153 0.076 1.118
SPINOFF? 0.573* 3.238 0.072 1.774
SIZE 0.000 2.441 0.118 1.000
CAPITAL RAISED PER EMPLOYEE 0.000 0.230 0.631 1.000
CAPITAL MARKET LINKAGES 0.002 0.420 0.517 1.002
OBSTACLE CAPITAL 0.443 1.223 0.269 1.557
STAGE—RD 0.196 0.240 0.624 1.217
STAGE—PRECLINICAL 20.758 1.213 0.271 0.468
STAGE—REGULATORY 2.564** 4.699 0.030 12.992
IPINF 20.616 1.811 0.178 0.540
IPOUTF 1.277*** 7.219 0.007 3.585
IPINC 20.227 0.233 0.629 0.797
IPOUTC 20.355 0.484 0.487 0.701
Constant 23.211 19.499 0.000 0.040
R2 0.426
*, **, ***Significant at 0.1, 0.05 and 0.01, respectively.
aLogistic regression results are fairly easy to interpret; logistic regression results allow one
to estimate directly the probability of an event occurring. The parameters of a model are
estimated using the maximum-likelihood method; that is, the coefficients that make the
observed results most likely are selected. In general, the left-hand side of a logistic
regression is ‘‘logit’’ or ‘‘log odds ratio’’. In the case of a model that predicts whether or not a
firm patents the model is:
Logit (patent)5Constant+B1*RDSPEND+B2*INHASTECH+B3*BIORCRT …
The ‘‘B’’ associated with each independent variable is the portion of the log odds ratio that is
attributable to that variable. In the logistic model, which predicts whether or not a firm
patents, the B associated with ‘‘BIORCRT’’, for example, is 0.434. The ‘‘Wald’’ associated
with each independent variable refers to the Wald statistic, which is in this case similar to a
chi-square statistic, and provides an estimate of the significance of the variable. In the case
of ‘‘BIORCRT’’ the Wald statistic is 21.465, which will occur less then one thousand of a
percent of the time by chance alone, hence it is significant (see Sig.).
The final value presented for each independent variable is the exponential of B (the log odds
ratio), or the simple odds ratio associated with a one-unit change in the independent
variable in terms of the dependent variable. If B is positive, its exponent will be greater than
1, which means the odds will increase. If B is negative, the exponent will be less than one,
which means that the odds will decrease. In the case of ‘‘BIORCRT’’, for example, a firm
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they used a higher number of different recruiting methods to fill biotech
positions. The intensity of patenting was also positively associated with in-
house R&D capability.
In contrast to the first model, firms that patent more intensively have a
higher proportion of their products and processes at an earlier (R&D) stage
of development. Furthermore, the innovation intensity model supports
previous research on the importance of VC: patenting firms are more
successful in accessing capital from angel investors, family, friends, VC
funds and collaborative alliances, that is, private, relational capital market
linkages.8 Innovative firms are also less likely to rely on government
sources of information. The evidence on IP flows is somewhat ambiguous.
On the one hand, as in the first model, innovative firms are more likely to
transfer IP rights to foreign firms than are less innovative firms. On the
other hand, they are also less likely to acquire IP rights from foreign firms.
This suggests that technologically progressive (i.e. patent-intensive) firms
are less dependent on foreign codified knowledge inputs (at least those
acquired through formal IP agreements), being able to satisfy their
knowledge requirements from local or internal sources.
To get a deeper understanding of the relative significance of local and
global networks, we produced a number of cross-tabulations of the survey
data. First, we explored the relationship between innovation (patenting)
and the presence of foreign biotech employees (see Table 6). Interestingly,
we found that innovative firms are almost six times more likely to hire
foreign employees than are non-innovative ones. We also examined the
relationship between patenting and flows of knowledge (intellectual
property). The findings show that patenting firms are about two and a
half times more likely to grant IP rights to foreign firms compared to non-
patenting ones. They are also almost twice as likely as non-innovative
companies to acquire IP rights from foreign firms. Taken together, these
findings appear to highlight the importance of strong external—indeed
global—knowledge flows (both embodied and disembodied) in the
innovative success of Canadian biotech firms.
8 Unfortunately, the survey design does not permit us to determine the location of these
private/relational sources.
that uses two recruiting methods is 1.5432 or 2.381 times more likely to innovate than a firm
that uses only one recruiting method; a firm that utilizes three methods is 1.5433 or 3.674
times as likely to innovate as a firm that uses only one method. In the case of a dummy
variable, such as the numerical value assigned to the yes/no answer of ‘‘IPOUTF’’ an
exp(B) value of 3.585 simply means that a firm that grants a right to foreign firms is about
three and a half times more likely to innovate than a firm that does not grant such rights (this
explanation is derived from Daniere and Takahashi (1999) and Norusis and SPSS Inc.
(1990)).
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To further understand the nature of these global partnerships and
collaborative arrangements, we explored the geography of these agree-
ments more explicitly. Recall that the findings reported in Table 4 indicated
a positive relationship between patenting and the number of collaborative
agreements in which the firm is engaged. Table 7 shows that the
Table 6. Biotech innovation and global knowledge flows
Does the firm
innovate?
Foreign
employees? (%)a
IP acquired from
foreign firms (%)a
IP granted to foreign
firms (%)a
Yes No Yes No Yes No
Yes 29.0 71.0 23.0 77.0 21.9 78.1
No 5.3 94.7 12.1 87.9 8.3 91.7
aChi-square significant at 0.01.
Table 5. Linear regression analysis—number of existing/pending patents
Variable B Sig.
RDSPEND 8.50126 0.164
INHSTECH 0.486* 0.103
BIORCRT 0.232*** 0.002
KNOWFLWGG 20.110 0.778
OBSTHR 20.180 0.495
INTERNAL 26.622 0.858
CODIFIED 20.202 0.247
TACIT 0.184 0.160
GOVERNMENT 20.441*** 0.005
NUMBER OF COLLABORATIVE AGREEMENTS 20.45722 0.351
SPINOFF? 0.363 0.208
SIZE 22.12724 0.207
CAPITAL RAISED PER EMPLOYEE 2.79326 0.777
CAPITAL MARKET LINKAGES 7.66923** 0.020
OBSTACLE CAPITAL 0.144 0.659
STAGE—RD 1.257*** 0.000
STAGE—PRECLINICAL 0.582 0.284
STAGE—REGULATORY 0.947 0.342
IPINF 20.808** 0.047
IPOUTF 1.043*** 0.011
IPINC 0.105 0.796
IPOUTC 0.712 0.117
Constant 20.829 0.155
R2 0.209
*, **, ***Significant at 0.1, 0.05 and 0.01, respectively.
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geography of this collaboration exhibits a strong distance-decay effect. In
short, geography matters for collaboration: Canadian biotech firms are
more likely to engage in collaborative agreements with Canadian partners.9
Having said this, analysis of the relationship between patenting and
collaboration by country suggests a stronger relationship between
collaboration and patenting when the partners involved are American or
European (Table 8). Amongst all firms, 42.5 percent report an existing or
pending patent. If, on the other hand, the firm has a collaborative
agreement with an American or European partner, the innovation rate
increases to between 60 and 61 percent. While a similar relationship is
evident when the firm collaborates with a Canadian partner, this effect
appears to be somewhat weaker. For those firms with a Canadian
collaborator, the proportion that patents is just under 51 percent. In other
words, although collaboration with Canadian partners is more prevalent
than international collaboration, the impact of this collaboration on the
likelihood of patenting is not as great as the impact of international (US or
European) collaboration.
9 It should be acknowledged that, although we are defining ‘‘distance’’ in traditional physical
terms here, it is highly likely that cultural or institutional distance is equally relevant to this
discussion, as Gertler (2004) has demonstrated.
Table 7. The geography of collaboration
Country No. of collaborative agreements
Canada 326
USA 159
Europe 99
Rest of world 52
Table 8. Innovation and collaboration geography
Does the
firm
innovate?
Canadian
collaborators (%)a
American
collaborators (%)a
European
collaborators (%)a
AllYes No Yes No Yes No
Yes 50.8 32.5 60.2 34.2 60.8 37.3 42.5
No 49.2 67.5 39.8 65.8 39.2 62.7 57.5
aChi-square significant at 0.01.
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Conclusions: A Complex Geography of Global and Local Linkages
The results presented in this paper illuminate the two sides of the
innovation process in biotechnology: the local and the non-local/global.
They also underscore the importance of internal resources and compe-
tences in permitting the firm to make the best use of opportunities for
learning-by-interacting. Our analysis of the 1999 Canadian Biotech Use
and Development Survey highlights the importance of in-house technolo-
gical capability (and absorptive capacity) for the success of innovation in
biotechnology, as was demonstrated by the importance of in-house R&D
and the intensity of efforts to recruit biotech workers. These results are in
line with findings from previous work that emphasizes the importance of
a firm’s internal resources and capabilities (Penrose, 1959; Kay, 1993;
Cohendet et al., 1999).
However, our analysis also provides some new and more detailed
insights into the geography of knowledge flows supporting innovation in
biotech firms. The findings suggest that to be successful innovators,
Canadian biotech firms must be externally oriented. Patenting biotech firms
make more extensive use of codified sources of knowledge, and are more
likely to recruit staff from outside Canada than are non-patenting firms. This
implies a substantial reliance on non-local sources of knowledge and on
international knowledge flows (embodied and otherwise). In addition, while
innovative firms make more extensive use of collaborative arrangements
than non-innovative firms, and while the majority of collaborative partners
are to be found in Canada, the presence of a foreign partner in such a
relationship appears to be more strongly associated with patenting than is
the presence of a Canadian partner. Finally, patenting firms are more likely
than non-patenting firms to grant IP rights from their research to foreign
firms, suggesting the importance of global relationships for the commer-
cialization of knowledge once produced.
Although we highlight the importance of global networks in our findings,
our analysis also reveals the value of local networks. The clearest
suggestion of this comes in our finding that ‘‘local’’/relational linkages are
especially important for raising capital (and, presumably, the expertise that
comes with it). While it is highly likely that angel investors, family and
friends are truly local, when it comes to VC and financing from collaborative
alliances, the relevant partners may not necessarily be local (although the
literature suggests that there is still a strong probability that they will be
close by).
The striking evidence on the external orientation of innovative biotech
firms in Canada dispels some of the ambiguity evident from previous work.
Whereas researchers have noted the importance of local sources of VC
and knowledge (Niosi, 2000b; Cooke, 2002a), others argue that knowledge
flows are becoming more dispersed (Cortright and Mayer, 2002). We show
that in Canada both knowledge flows and capital flows (in the form of
payments received from licensing IP) are increasingly extending beyond
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the immediate locality and nation to foreign partners and sources. This
external orientation may be a product of both the location and the age of
the industry. Possibly, as suggested by the Ernst and Young (2002) review
of biotech in Canada, the limitations to the entrepreneurial experience and
local financial resources available to Canadian biotech firms relative to their
counterparts in the USA, the UK or other European countries, compel
these firms to search elsewhere for the capital and expertise that would
enhance their chances of commercial success. Second, the above results
may also reflect the changing nature of innovation in a maturing biotech
industry. It is likely that as firms expand, grow and develop they will need to
extend their search to resources and markets located farther away.
Thinking more broadly about the implications of our analysis for a
theory of biotech clusters, it seems clear that innovative biotechnology
firms must be both open to new knowledge (embodied and otherwise) from
a wide range of sources and reliant on local relationships for capital and
know-how. This suggests that those places that are best suited to fostering
innovation in biotechnology will not simply be places that provide local
‘‘buzz’’, but must also be well connected to globally circulating knowledge
and people. If so, then how should we understand the role of place in
supporting biotech innovation? In other words, why is it that biotech firms
cluster in relatively few places, and why is this geography becoming more
concentrated over time, not less?
We suggest that innovative biotech firms cluster geographically for two
basic reasons. First, as the Novartis case suggests, they choose those
locations that maximize opportunities to benefit from local relationships with
other firms,10 investors, and institutions of research and higher learning
(producers of knowledge in embodied and disembodied forms).11 Second,
they select those places that best enable them to attract and retain their most
critical resource—highly educated workers—from elsewhere but also, we
can infer, from local sources. Recent research on this subject suggests that
local quality of place—broadly defined to include not only the usual list of
physical, recreational and cultural amenities, but also social characteristics
such as low ‘‘barriers to entry’’ and the presence of a critical mass of creative
people—is vital to ensure that local communities are open to inflows of
knowledge and talent (Florida, 2002; Gertler et al., 2002).
Nevertheless, despite the importance of ‘‘the local’’, it is clear from the
analysis in this paper that strong linkages to foreign markets, collaborators,
labour pools and other sources of knowledge remain crucial for enabling
innovation in biotechnology firms.
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